Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MacroGenics, Inc. (MGNX : NSDQ)

• Company Description    MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. Number of Employees: 293

• Price / Volume Information    Yesterday's Closing Price: $3.70 Daily Weekly Monthly 20 Day Moving Average: 1,175,385 shares Shares Outstanding: 63.56 (millions) Market Capitalization: $235.18 (millions) Beta: 1.18 52 Week High: $5.08 52 Week Low: $1.29 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.60% -21.18% 12 Week 20.13% 16.84% Year To Date 129.81% 130.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9704 MEDICAL CENTER DRIVE - Rockville,MD 20850 USA ph: 301-251-5172 fax: 301-251-5321 info@macrogenics.com http://www.macrogenics.com

• General Corporate Information    Officers Eric Risser - Chief Executive Officer;President and Director James Karrels - Senior Vice President and Chief Financial Office Karen Ferrante - Director William Heiden - Director Edward Hurwitz - Director Peer Information MacroGenics, Inc. (BJCT) MacroGenics, Inc. (CADMQ) MacroGenics, Inc. (APNO) MacroGenics, Inc. (UPDC) MacroGenics, Inc. (IMTIQ) MacroGenics, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 556099109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 63.56 Most Recent Split Date: (:1) Beta: 1.18 Market Capitalization: $235.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 11.09 Price/Cash Flow: - Price / Sales: 1.50 EPS Growth vs. Year Ago Period: 10.77% vs. Previous Quarter: -163.64% Sales Growth vs. Year Ago Period: 57.48% vs. Previous Quarter: -49.61% ROE 06/30/26 - - 03/31/26 - -147.80 12/31/25 - -120.19 ROA 06/30/26 - - 03/31/26 - -28.40 12/31/25 - -29.92 Current Ratio 06/30/26 - - 03/31/26 - 1.90 12/31/25 - 5.10 Quick Ratio 06/30/26 - - 03/31/26 - 1.80 12/31/25 - 4.92 Operating Margin 06/30/26 - - 03/31/26 - -44.79 12/31/25 - -49.91 Net Margin 06/30/26 - - 03/31/26 - -44.79 12/31/25 - -49.91 Pre-Tax Margin 06/30/26 - - 03/31/26 - -45.22 12/31/25 - -50.36 Book Value 06/30/26 - - 03/31/26 - 0.33 12/31/25 - 0.88 Inventory Turnover 06/30/26 - - 03/31/26 - 4.53 12/31/25 - 4.07 Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©